Crescent Biopharma (CBIO) EBITDA Margin (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly EBITDA Margin of 2380.08% for Q1 2026, up 86.63% quarter-over-quarter from 17804.21% in Q2 2022.
Crescent Biopharma (CBIO) EBITDA Margin (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported EBITDA Margin for 8 consecutive years, with 2380.08% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin changed N/A year-over-year to 2380.08%; the TTM figure through Jun 2026 stood at 16214.63% (changed N/A YoY), while the FY2025 annual figure was 1407.52%, changed N/A from the prior year.
- EBITDA Margin rose to 2380.08% in Q1 2026 per CBIO's latest filing, from 17804.21% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2380.08% in Q1 2026 and bottomed at 17804.21% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,380.08% |
| Jun 30, 2022 | -17,804.21% |
| Dec 31, 2021 | -98,870.20% |
| Sep 30, 2021 | -20,028.82% |
| Jun 30, 2021 | -10,144,001.41% |
| Mar 31, 2021 | -1,352.98% |
| Dec 31, 2020 | -9,554.94% |
| Sep 30, 2020 | -1,372.73% |
| Mar 31, 2020 | -90.09% |
| Sep 30, 2016 | -42,631.11% |
| Dec 31, 2015 | -25,123.75% |
| Sep 30, 2015 | -20,272.43% |
| Jun 30, 2015 | 51.93% |
| Jun 30, 2014 | 53.66% |
| Dec 31, 2013 | -4,995.73% |
| Sep 30, 2013 | -7,039.81% |
| Jun 30, 2013 | -6,349.56% |
| Mar 31, 2013 | 12.05% |